A phase III clinical trial to evaluate patient's preference of subcutaneous trastuzumab (SC) versus intravenous (IV) administration in patients with HER2 positive Advanced Breast Cancer (ABC) who have received intravenous trastuzumab at least 4 months and without disease progression

Trial Profile

A phase III clinical trial to evaluate patient's preference of subcutaneous trastuzumab (SC) versus intravenous (IV) administration in patients with HER2 positive Advanced Breast Cancer (ABC) who have received intravenous trastuzumab at least 4 months and without disease progression

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ChangHER-SC
  • Most Recent Events

    • 30 Mar 2017 Planned End Date changed from 1 May 2016 to 1 Jul 2018.
    • 30 Mar 2017 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2018.
    • 30 Mar 2017 Status changed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top